ICU Medical (ICUI) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICU Medical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ICUI shares.
View ICUI analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1-year price objectives for ICU Medical's shares. Their ICUI share price forecasts range from $190.00 to $216.00. On average, they expect the company's share price to reach $203.00 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts price targets for ICUI or view top-rated stocks among Wall Street analysts.

ICU Medical's stock was trading at $157.48 at the start of the year. Since then, ICUI stock has increased by 17.1% and is now trading at $184.46.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ICUI earnings forecast.

ICU Medical, Inc. (NASDAQ:ICUI) released its quarterly earnings data on Wednesday, November, 3rd. The medical instruments supplier reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.57 by $0.50. The medical instruments supplier had revenue of $336.06 million for the quarter, compared to analyst estimates of $314.20 million. ICU Medical had a positive trailing twelve-month return on equity of 6.42% and a negative net margin of 2.00%. During the same quarter last year, the company posted $1.61 earnings per share.

ETFs with the largest weight of ICU Medical (NASDAQ:ICUI) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), First Trust Health Care AlphaDEX Fund (FXH), VanEck Morningstar SMID Moat ETF (SMOT), FIS Knights of Columbus Global Belief ETF (KOCG), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares S&P Mid-Cap 400 Value ETF (IJJ), SPDR S&P 400 Mid Cap Value ETF (MDYV) and Vanguard S&P Mid-Cap 400 Value ETF (IVOV).

81 employees have rated ICU Medical Chief Executive Officer Vivek Jain on Glassdoor.com. Vivek Jain has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ICU Medical investors own include Becton, Dickinson and (BDX), BlackRock (BLK), NVIDIA (NVDA), Alibaba Group (BABA), CA (CA), UnitedHealth Group (UNH), Boeing (BA), Micron Technology (MU), Lockheed Martin (LMT) and ServiceNow (NOW).

ICU Medical trades on the NASDAQ under the ticker symbol "ICUI."

ICU Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.19%), BlackRock Inc. (7.30%), JPMorgan Chase & Co. (3.24%), State Street Corp (2.56%), Victory Capital Management Inc. (2.49%) and Nuance Investments LLC (2.14%). Insiders that own company stock include Daniel Woolson, Elisha W Finney, George A Lopez, Robert S Swinney, Virginia Ruth Sanzone and Vivek Jain.
View institutional ownership trends.

Shares of ICUI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICUI stock can currently be purchased for approximately $184.46.

ICU Medical (NASDAQ:ICUI) has a market capitalization of $4.44 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $-74,290,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

The company employs 14,500 workers across the globe.

ICU Medical's mailing address is 951 CALLE AMANECER, SAN CLEMENTE CA, 92763. The official website for the company is www.icumed.com. The medical instruments supplier can be reached via phone at (949) 366-2183, via email at ir@icumed.com, or via fax at 949-366-8368.